OBJECTIVES: To evaluate hyaluronan-mediated motility receptor (RHAMM) expression in normal, hyperplasic and neoplastic prostate tissue following various types and durations of androgen deprivation.
Clinical and oncological data from men with localised prostate adenocarcinoma (PCa) were also assessed and compared to RHAMM expression data.
PATIENTS AND METHODS: Data from 367 men who underwent histological evaluation of the prostate were retrospectively evaluated under 6 conditions: 1) benign prostatic hyperplasia (BPH), 2) BPH treated with finasteride, 3) PCa without ADT, 4) PCa treated with neoadjuvant ADT prior to prostatectomy (cyproterone 200 mg/day), 5) CRPC, and 6) normal peritumoural prostate tissue. Tissue microarrays were constructed, and 1,354 cores were evaluated for immunohistochemical RHAMM expression.
RESULTS: No RHAMM expression was observed in any tissue from normal patients or those with BPH or PCa without ADT. RHAMM expression was observed in 39.4% of PCa tissues treated with ADT and in 46.2% of CRPC samples (p=0.001). There was a significant increase in RHAMM expression with increased ADT duration in group 4, with a marked increase in RHAMM expression after 6-12 months of ADT (p=0.04). No prognostic or clinical factors related to PCa were associated with RHAMM expression.
CONCLUSIONS: RHAMM expression in PCa is directly associated with ADT. Significant RHAMM expression occurs as early as after one month of ADT and progressively increases with ADT duration. When PCa becomes CRPC, RHAMM expression is higher. RHAMM expression was not associated with PCa prognostic factors. RHAMM overexpression may contribute to the development of hormonal resistance in PCa.
Written by:
Korkes F, Castro MG, Zequi SD, Nardi L, L Giglio A, Peo AC. Are you the author?
Division of Urology, ABC Medical School.
Reference: BJU Int. 2013 Jul 2. Epub ahead of print.
doi: 10.1111/bju.12339
PubMed Abstract
PMID: 24053431
Go "Beyond the Abstract" - Read an article written by the authors for UroToday.com
UroToday.com Investigative Urology Section
